KR960705925A - Hu-B1.219, 신규한 사람 조혈 수용체(Hu-B1.219, A NOVEL HUMAN HEMA-TOPOIETIN RECEPTOR) - Google Patents

Hu-B1.219, 신규한 사람 조혈 수용체(Hu-B1.219, A NOVEL HUMAN HEMA-TOPOIETIN RECEPTOR)

Info

Publication number
KR960705925A
KR960705925A KR1019960702513A KR19960702513A KR960705925A KR 960705925 A KR960705925 A KR 960705925A KR 1019960702513 A KR1019960702513 A KR 1019960702513A KR 19960702513 A KR19960702513 A KR 19960702513A KR 960705925 A KR960705925 A KR 960705925A
Authority
KR
South Korea
Prior art keywords
receptor
topoietin
hema
human
new
Prior art date
Application number
KR1019960702513A
Other languages
English (en)
Other versions
KR100245529B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/306,231 external-priority patent/US5643748A/en
Application filed filed Critical
Publication of KR960705925A publication Critical patent/KR960705925A/ko
Application granted granted Critical
Publication of KR100245529B1 publication Critical patent/KR100245529B1/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
KR1019960702513A 1994-09-14 1995-08-30 Hu-b1.219,신규한 사람 조혈 수용체 KR100245529B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/306,231 US5643748A (en) 1994-09-14 1994-09-14 HU-B1.219, a novel human hematopoietin receptor
US306231 1994-09-14
US355888 1994-12-14
US08/355,888 US5763211A (en) 1994-09-14 1994-12-14 Isolated nucleic acid encoding Hu-B1.219, a novel human hematopoietin
PCT/US1995/010965 WO1996008510A1 (en) 1994-09-14 1995-08-30 Hu-B1.219, A NOVEL HUMAN HEMATOPOIETIN RECEPTOR

Publications (2)

Publication Number Publication Date
KR960705925A true KR960705925A (ko) 1996-11-08
KR100245529B1 KR100245529B1 (ko) 2000-02-15

Family

ID=26975043

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702513A KR100245529B1 (ko) 1994-09-14 1995-08-30 Hu-b1.219,신규한 사람 조혈 수용체

Country Status (2)

Country Link
US (1) US5763211A (ko)
KR (1) KR100245529B1 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN564195A0 (en) * 1995-09-26 1995-10-19 Walter And Eliza Hall Institute Of Medical Research, The A novel haemopoietin receptor and genetic sequences encoding same
US6506877B1 (en) * 1995-11-27 2003-01-14 Millennium Pharmaceuticals, Inc. Ob receptor
US6287782B1 (en) * 1995-11-27 2001-09-11 Millennium Pharmaceuticals, Inc. Methods of using the Ob receptor to identify therapeutic compounds
US6509189B1 (en) * 1995-11-27 2003-01-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding the cytoplasmic domain of human Ob receptor
US6548269B1 (en) * 1995-11-27 2003-04-15 Millennium Pharmaceuticals, Inc. Ob receptor and methods for the diagnosis and treatment of body weight disorders, including obesity and cachexia
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US7074397B1 (en) * 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) * 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7148004B1 (en) * 1997-01-16 2006-12-12 The Rockefeller University Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US20020081602A1 (en) * 1996-11-01 2002-06-27 Smithkline Beecham P.1.C. Method for the detection of compounds that modulate the effects of the obese (ob) protein
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
US6770444B2 (en) 1998-07-16 2004-08-03 Synaptic Pharmaceutical Corporation Methods of identifying or screening for agents that binds the Ob-Re
CA2285700C (en) * 1998-10-13 2005-12-06 Tokiwa Chemical Industries Co., Ltd. Renin-active substance
AU767068B2 (en) * 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002757A1 (en) * 1986-10-17 1988-04-21 Saramane Pty. Ltd.; Hybrid proteins or polypeptides
DE122009000023I2 (de) * 1989-07-20 2010-12-16 Kishimoto Antikörper gegen menschlichen Interleukin-6-Rezeptor
JP3403403B2 (ja) * 1990-03-23 2003-05-06 財団法人大阪バイオサイエンス研究所 顆粒球コロニー刺激因子レセプターをコードするｄｎａ
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US6274708B1 (en) * 1994-09-05 2001-08-14 Amrad Operations Pty Ltd. Mouse interleukin-11 receptor

Also Published As

Publication number Publication date
US5763211A (en) 1998-06-09
KR100245529B1 (ko) 2000-02-15

Similar Documents

Publication Publication Date Title
FI916165A0 (fi) 1,3-oxatiolannukleosidanaloger.
NO2006016I1 (no) 7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat
PT993456E (pt) 4,5-diaril-imidazoles 2-substituidos
FI953489A (fi) 2,6-diaminopuriinijohdannaisia
DK0771789T3 (da) 1 alpha, 26-dihydroxy-D-homo-vitamin D3
NO951442D0 (no) 3,5-disubstituerte tetrahydrofuran-2-oner
KR960705925A (ko) Hu-B1.219, 신규한 사람 조혈 수용체(Hu-B1.219, A NOVEL HUMAN HEMA-TOPOIETIN RECEPTOR)
TR27961A (tr) Sübstitüe edilmis 1,2,3,4 -tetrahidro-5-nitro-pirimidinler.
AT397656B (de) (6,7-substituierte-8-alkoxy-1-cyclopropyl-1,4-
NO960223D0 (no) 2,9-disubstituerte purin-6-oner
ID21413A (id) Turunan-turunan 1,3,8,-triaza-spiro (4,5) dekan-4-on
BR9609884A (pt) N-aril- 1,2,4-triazolin-5-onas
DE69618634T2 (de) 1,4-benzodioxin-derivate
DK0874814T3 (da) 25-hydroxy-16-en-26,27-bishomo-cholecalciferoler
FI1592U1 (fi) Spruta, foeretraedesvis injektionsspruta
ATE121400T1 (de) Pyridyl-methylenamino-1,2,4-triazinone.
DK1068200T3 (da) 2,4,4-trisubstituerede-1,3-dioxolanfungicider
ID24047A (id) Turunan 5-tersubstitusi-3-oksaziazolil 1,6-naftiridin-2 1h-on
BR9508248A (pt) 1,2,4,6-Tiatriazinas herbicidas
NO962931L (no) N,N-dietyl-8,8-dipropyl-2-azaspiro£4,5|decan-2-propanamindimaleat
FI906269A0 (fi) 2,19-metylenoxi- och 2,19-metylentio -tvaerbundna steroider som aromatas- och 19-hydroxylasinhibitorer.
NO944024L (no) 1,2-dihydro-2-okso-pyridin
BR9610047A (pt) 1,3,4-oxadiazolin-2-onas
ITMI941593A1 (it) Tetraidropiridine 3, 3-disostituite
FI924721A0 (fi) 2,3-dideoxy-4-tioribonukleosider som antivirala aemnen

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B701 Decision to grant
GRNT Written decision to grant
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
FPAY Annual fee payment

Payment date: 20071123

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee